Genomic patterns of nasopharyngeal carcinomas (NPCs) have as yet been studied in Southeast Asian (SEA) patients. Here, we investigated genomic patterns of locally advanced NPC Southeast European (SEE) patients treated with chemoradiotherapy. We examined 126 tumors (89% EBV positive) from Greek and Romanian NPC patients with massively parallel sequencing. Paired tumor-cell-rich (TC) and infiltrating-lymphocyte-rich (TILs) samples were available in 19 and paired tumor-germline samples in 68 cases. Top mutated genes were BRCA1 (54% of all tumors); BRCA2 (29%); TP53 (22%); KRAS (18%). Based on the presence and number of mutations and mutated genes, NPC were classified as stable (no mutations, n 5 27); unstable (>7 genes with multiple mutations, all BRCA1 positive, n 5 21); and of intermediate stability (1-7 singly mutated genes, n 5 78). BRCA1 p.Q563* was present in 59 tumors (48%), more frequently from Romanian patients (p < 0.001). No pathogenic germline mutations were identified. NPC exhibited APOBEC3A/B and nucleotide-excision-repair-related mutational signatures. As compared to TC, TILs demonstrated few shared and a higher number of low frequency private mutations (p < 0.001). In multivariate analysis models for progressionfree survival, EBV positivity was a favorable prognosticator in stable tumors; BRCA1 mutations were unfavorable only in tumors of intermediate stability. In conclusion, other than described for SEA NPC, somatic BRCA1 mutations were common in SEE NPC; these were shared between TC and TILs, and appeared to affect patient outcome according to tumor genomic stability status. Along with the identified mutational signatures, these novel data may be helpful for designing new treatments for locally advanced NPC.
Introduction
Nasopharyngeal carcinoma (NPC) is rare in Europe and most parts of North America with a crude annual rate of 0.1-1.1/100,000 people. 1 Incidence rates are highest in certain areas of the globe, such as Southeast Asia, Southern Asia, Alaska and Mediterranean Basin; in Southeast Europe, the annual incidence is 1/100,000. 2 It is estimated that 87,000 new cases (0.6% of all cancers) were diagnosed and 51,000 deaths occurred in 2012 worldwide. 3 The remarkably distinctive geographic and ethnic distribution is suggestive for a strong link between NPC and genetic/environmental factors. 4 The development of NPC is undeniably associated with infection by the Epstein-Barr virus (EBV). The undifferentiated type, strictly associated with EBV infection, is predominant in endemic areas, while the differentiated and non-keratinizing squamous cell variants are common in the USA and North European countries. 5 Radiation therapy (RT) appears to be the treatment of choice for early stages, 6 while the combination of RT with chemotherapy is necessary for the management of locally advanced disease, where RT alone represents a poor therapeutic option. Indeed, a number of meta-analyses interrogating the effect of concomitant-radiotherapy (CRT) over RT alone, clearly and repeatedly showed the superiority of CRT in terms of locoregional control, progression-free survival and overall survival (OS), offering an absolute benefit of 6.3% for OS at 5 years. 7, 8 However, even after the application of the optimal treatment, many patients with NPC and especially those with locally advanced tumors eventually succumb to their disease. These dismal results prompted for intensive research efforts toward advancing information about NPC pathogenesis and biologic characteristics. The advent of high-throughput technologies offered tremendous opportunities to deepening our understanding of the biology underpinning a number of human diseases including cancer. Of note, recently published studies begun to shed light to the genomic background of NPC revealing novel actionable genomic alterations and important pathways for the survival of cancer cells. [9] [10] [11] Nonetheless, these pioneer studies included patients of Asian origin. Evidently, the need to expand genomic information in other ethnic groups and in parallel increase the number of molecularly screened samples is imperative. Notably, similar studies describing the genomic landscape of European patients with NPC and specifically from Southern Europe, where the incidence of the disease is several-fold higher than in Northern Europe are lacking from the literature.
In our study, we investigated tumor genotypes in Greek and Romanian patients with locally advanced NPC treated either with concomitant CRT (CCRT) or induction chemotherapy followed by CRT (IC-CCRT) in the context of a randomized phase II study 12 and in an extended cohort including exclusively Greek patients that received the same regimens as the patients that were treated within the randomized study. Here, we focused on the presence and patterns of NPC mutations in tumor tissues, and on their associations with standard clinicopathological characteristics, geographic diversity and patient outcome.
Patients and Methods
Prospectively collected formalin-fixed paraffin-embedded (FFPE) tumor tissue blocks from 154 Greek and Romanian patients with locally advanced NPC were retrieved from the Hellenic Cooperative Oncology Group (HeCOG) Tumor Repository and analyzed retrospectively in the Laboratory of Molecular Oncology (MOL, by the Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece). Tissue and blood specimens were collected before treatment, at baseline. Germline DNA from peripheral blood was available for 81 patients. Patients had been treated in the context of a previously published randomized phase II trial by HeCOG with cisplatin-based CCRT and with IC-CCRT 12 or received the same treatment in HeCOG affiliated centers after the end of the trial recruitment period. Romanian patients were treated at the "Ion Chiricuta" Cancer Institute (Cluj, Romania 
What's new?
The prognosis for nasopharyngeal carcinoma (NPC) may be extremely poor, and new therapeutic targets are urgently needed. High-throughput genomic studies have begun to implicate a number of mutations and pathways in NPC carcinogenesis. However, few studies have examined non-Asian ethnic groups. In this study of Southeast European patients, the authors found that more than half of NPCs carried somatic mutations in BRCA1 and other homologous-recombination repair genes as well as differences in tumor-infiltrating lymphocytes. Alternative treatments such as PARP-inhibitors may prove useful in these patients.
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Tumor characterization and FFPE sample processing for genotyping
Central histologic review of all tumor blocks and evaluation of in situ methods was performed by expert pathologists (T.Z. and M.B). Tumors were typed for latent EBV infection with in situ hybridization for the detection of Epstein Barr encoded RNA (EBER), by two experienced pathologists (D.R. and M.B), as described. 13 In tumors without available tissue for ISH, EBV
was assessed with polymerase chain reaction (PCR) for EBER1 with published primers. 14 Tumors were also assessed with immunohistochemistry for p16 protein expression as a surrogate for HPV infection 15 and for PDL-1, for which we used the CAL10 monoclonal antibody (Biocare Medical, Pacheco, CA) at 1:75 dilution. As per manufacturer, CAL10 detects PD-L1 on cell membranes and cytoplasm and, as there is no proposed cutoff for this antibody, tumors were considered positive for any staining pattern at any percentage. Hematoxylin and eosin (H&E) sections were evaluated for tumor cell content (TCC%) and tumor infiltrating lymphocytes (TILs%) for genotype comparisons in the two compartments of the same tumor. Where possible, tumor-cell-rich and TILs-rich areas were marked on H&Es and macrodissected for DNA extraction, as described in Supporting Information Methods and Figure S1 .
FFPE DNA was extracted from 10 lm unstained sections according to standard procedures with the QIAamp DNA Mini Kit (Qiagen GmbH, Hilden, Germany). Germline DNA was extracted from peripheral blood enucleated cells with the salt extraction procedure. 16 21 VAF differences >|20| affecting clonality status were used for inferring mutation origin from tumor cells or lymphocytes in matched macrodissected samples (Supporting Information Methods). Mutation signatures were generated using the total variants that did not fit the common single nucleotide polymorphism (SNP) criteria (MAF >0.1%) across all patients, by performing a multiple regression approach on each group including EBV positive (n 5 2519), negative (n 5 433) and all cases (n 5 3,055). DeconstructSigs 22 was used to extract signatures based on the Wellcome Trust Sanger Institute Mutational Signature Framework and to statistically quantify the contribution of each signature for every category. The weights of each reference signature were iteratively inferred until an empirical error threshold was reached; signatures below 6% were dropped. The reconstructed mutational profile was determined after correcting for the sum-squared error (SSE) reflecting the difference between the fractions of mutations in each of the reference 96 trinucleotide contexts, by linearly combining the predefined signatures.
APOBEC3 gene expression profiling
RNA was extracted from whole FFPE sections with TRIZOL-LS, reversed transcribed and tested for the relative expression of APOBEC3A/B (Hs00377444_m1) that detects a deletion hybrid containing the promoter and coding region of APO-BEC3A and the 3 0 UTR of APOBEC3B; APOBEC3B (Hs00358981_m1) and APOBEC3C (Hs00828074_m1) transcripts, at default conditions in an ABI7900HT real time PCR system (all reagents and systems from Thermo-Fisher Scientific/Applied Biosystems), with standard methods as described previously. 23 
Statistics
Categorical data are presented as frequencies and corresponding percentages; continuous data are presented as mean, standard deviation, median and range values. The Fisher's exact or Pearson v 2 tests were used for group comparison of categorical data, while for continuous data the t test or the non-parametric Mann-Whitney test were used where appropriate.
Overall survival (OS) was measured from the date of randomization to patient's death or last contact. Progression free survival (PFS) was measured from the date of randomization to documented disease progression, death without prior documented progression or last contact. Patients who survived without relapse were censored at the date of their last contact. Survival curves were estimated using the KaplanMeier method and compared across groups with the log-rank test.
The associations between factors of interest and relapse/ mortality rate were evaluated with hazard ratios estimated with univariate and multivariate Cox proportional hazards models. The associations between factors of interest and tumor response to treatment were evaluated with odds ratios estimated with univariate logistic regression models. For multivariate analysis, the effects of PFS/OS for the following factors were adjusted: age (median cut off; 52.5 vs. <52.5); gender (male vs. female); geographical origin (Romanian vs. All patients were initially staged according to the American Joint Committee on Cancer (AJCC, 7th edition). Patients were divided in two stage groups (I-III, IV) based on previously published results; patients with stage IVA/B bear significantly worse 5-year disease-specific survival than those with stage II or III 24 or overall survival. 25 Furthermore, patients with stage I disease comprise only a small minority and are accompanied by an excellent prognosis. Response to IC-CCRT and CCRT-only was assessed using CT or MRI images after treatment completion, based on the World Health Organization criteria. All analyses were performed with the SAS software (SAS for Windows, version 9.3, SAS Institute Inc., Cary, NC). Statistical significance was set at two-sided p 5 0.05. Study outline with respect to sample characteristics and presentation of results adheres to the REMARK guidelines. 26 
Results
Informative NGS data were obtained for 126 tumors (Supporting Information Fig. S2 ). Major patient and tumor characteristics are shown in Supporting Information Table S1 . Significant differences between Greek and Romanian patients were noticed with respect to age, performance and smoking status, probably by chance due to the small sample size. EBV was found in 89% of assessable tumors. p16 protein was expressed in only five tumors, in four of them concomitantly with EBV. This was not unexpected, as HPV positivity in NPC is rare in endemic areas, 27 while it has been linked to type I carcinomas in the USA. 28 Evidently, statistical analysis involving p16 was not possible.
NPC genotypes and their associations with clinicopathological and mechanistic characteristics
We identified 1,546 mutations in 89 of 101 panel genes, in the tumors from 99 of 126 patients (78.6%), with extensively diverse patterns (Fig. 1) . Top mutated genes were BRCA1 (70/126; 55.5%) and BRCA2 (42/126; 33.3%) (Supporting Information Table S3 ). BRCA1 mutations were mostly nonsense ( Fig. 1 inset) ; mutations in all other genes were predominantly missense. Top affected gene families were homologous recombination repair (HRR), cell signaling, chromatin remodeling, receptor tyrosine kinases and immune response related genes.
No mutations were detected in 27 tumors. In mutated tumors, the range of mutations and of mutated genes per tumor was 1-150 and 1-49, respectively (Supporting Information Fig. S4 ); 55.6% of the 99 tumors had >2 mutations and 50% had mutations in >2 genes, the latter mostly applicable for BRCA1 (Fig. 1 inset) . Based on the above variations in mutation range, 21 cases were naturally classified as hypermutated (Supporting Information Fig. S5 ) corresponding to 16 .7% of all cases and to 21.2% of mutated cases. Based on the similarities in NGS performance (sequencing depth) and in the number of common SNPs between groups, as explained in Supporting Information Methods, hypermutation (Supporting Information Fig. S5 ) and absence of mutations (Supporting Information Fig. S4 ) were true findings and not sequencing artifacts. Based on these observations, we classified NPC into (a) stable (tumors without mutations); (b) of intermediate stability (1-7 mutations without multiple mutations per gene) and (c) unstable (multiple mutations in >7 genes) (Fig. 2a ). All unstable tumors had mutated BRCA1, but BRCA1 mutations were also found in 49 additional tumors of intermediate stability (46% of all tumors; Fisher's exact p < 0.001). Except for BRCA1, mutations in additional HRR genes, in immune response related and mismatch repair genes, and in POLE were also mostly present in unstable tumors (all Fisher's exact p's < 0.001). Mutations in TP53, autophagy genes and the ARID chromatin modulators were not associated with genomic stability status, while only 10 of 25 KRAS mutated tumors were unstable (Fisher's exact p 5 0.001). Most mutations in tissues were present at low frequency (Supporting Information Fig. S6 ); only 412 of 1,562 (26.5%) were classified as clonal. These affected 68 genes and were mostly found in tumor-enriched samples (368 of 1,518 [32%] mutations) (Supporting Information Fig. S7 ); top genes with clonal mutations were BRCA1, BRCA2, PALB2 and TP53.
Recurrent mutations that are reported as pathogenic in the germline (ClinVar) were observed in BRCA1 with p.Gln563Ter (p.Q563*) present in 59 and BRCA2 p.Asp2723Gly (p.D2723G) in 13 cases. These BRCA1 and BRCA2 mutations were validated with Sanger sequencing ( Fig. 2b ; more cases validated for Total number of mutations per case is shown in the diagram on top; prevalence of mutated genes in the diagram on the left; classification of tumors for patient geographical origin and for EBV status is presented in the bottom bars; and, the incidence and type of BRCA1 mutations per tumor are shown in detail in the inset on the right. The colors for mutation types apply to the map and the inset. Top affected gene families were homologous recombination repair or HRR (BRCA1, BRCA2, PALB2, CHEK2, RAD21, RAD50 and BAP1 in 79 cases, 62.7%); cell signaling (all RAS genes, AKT1, AXIN1, BRAF, MAP2K2, PIK3CA and RANBP2 in 43, 34.1%); chromatin remodeling (all ARID, MLL and TET genes, DNMT3A, EZH2, KDM4A, SETD2, SMARCC1 and SRCAP in 41, 32.5%). Mutations in receptor tyrosine kinase genes (EGFR, ERBB2, ERBB3, FGFR2 and KIT) were observed in 39 cases (31%) and in immune response related genes (mostly PDL1, PD1 and CTLA4, but also CD3, CD8 and 8b, JAK1 and 2, LMO2 and PTPRC) in 32 (25.4%). Table S4 ). BRCA2 p.Asp2723Gly always coexisted with BRCA1 p.Gln563Ter. Tumors carrying p.Gln563Ter made up 46.8% of all tumors, 59.6% of mutated tumors and 84.3% of BRCA1 mutated tumors. BRCA1 p.Gln563Ter was more frequent and more often clonal in unstable tumors (Fig. 2c) . In addition, the classic KRAS p.Gly12Asp was identified in 10 cases, clonal in 2, coexisting with BRCA1 p.Gln563Ter in 8 tumors. KRAS p.Gly12Asp was validated with a routinely used qPCR assay in seven cases informative with this method (Supporting Information Table S4 ).
BRCA1 mutations and particularly p.Gln563Ter were significantly positively associated with APOBEC3A/B mRNA overexpression, while a negative association with mutation incidence was observed for APOBEC3C mRNA overexpression (Fig. 2d) . Analysis for mutation signatures showed the prevalence of C > T and specific C > G changes in the present NPC (Fig. 2e) . The corresponding mutation signatures differed between EBV positive and negative tumors (Fig. 2f) : the age-related Signature 1B was present in EBV negative but was absent in EBV positive tumors, in line with the older age of EBV negative patients in the present series (Mann-Whitney p 5 0.048). EBV positive exhibited the ultraviolet-lightrelated Signature 7, which was absent in EBV negative tumors. Independently of EBV status, NPC exhibited the ABOPEC3A/B-related Signature 2 and also Signature 11, which has been linked to alkylating agents and to transcription-coupled nucleotide-excision-repair, similar to Signature 7.
With respect to clinicopathological variables, the presence of any mutation, genomic stability status and gene specific mutations were not significantly related to gender, age, disease stage and EBV status. However, we observed significant genotype variations with respect to the geographical origin of NPC patients ( Table 1) . As compared to tumors from Greek patients, tumors from Romanian patients had a higher number of mutations (p 5 0.001), mutated genes (p 5 0.004), mutated tumors (p 5 0.036) and more frequently carried mutations in BRCA1 (p < 0.001), BRCA2 (p 5 0.047), KRAS (p < 0.001) and EGFR (p 5 0.017). The statistical significant differences in the latter three genes may just reflect the overall higher mutation burden in tumors from Romanian patients. Strikingly, the BRCA1 p.Gln563Ter was present in 74% of tumors from Romanian as compared to 40% of tumors from Greek patients (p < 0.001).
PD-L1 positivity in tumor cells was observed in 64 of 110 assessable NPC (58%). The number of mutations (p 5 0.037) and of mutated genes (p 5 0.039), unstable genomic status (p 5 0.029) and the presence of POLE mutations (p 5 0.002) were positively associated with PD-L1 positivity.
Genotype comparisons in matched samples
We evaluated 68 tumor-peripheral blood, 14 blood-TILsenriched and 19 tumor-enriched-TILs-enriched matched pairs; these were compared for shared and private mutations and for mutation clonality. Sequencing performance of matched samples was similar (Supporting Information Fig.  S8 ). We identified 13 mutations at germline VAFs in blood samples from 10 patients ( Table 2) , 12 of which were preserved at germline frequencies in matched tumor samples and in one case with available TILs-enriched sample. Importantly, none of these mutations was previously characterized as definitely pathogenic (cancer predisposing) or associated with NPC. The presumably benign MLH1 p.Ser406Asn was lost in the corresponding tumor, which nevertheless was unstable and carried a Sanger validated somatic BRCA1 p.Gln563Ter mutation at 48% VAF (Supporting Information  Table S4 , #RC-123). Of note, this was the only case among the 13 for which we identified some germline change that carried the recurrent BRCA1 p.Gln563Ter, in practically all cells including TILs that comprised half the cell population in the sample. Whether the germline MLH1 mutation, although presumably benign, contributed to the acquisition of the somatic BRCA1 mutation can certainly not be deduced from or further discussed based on the example of one tumor only.
Comparison between tumor-enriched and TILs-enriched samples revealed 318 mutations that were evaluated in 15 of 19 (78.9%) sample pairs. In these pairs, 23 (7.2%) mutations were shared in both samples and are shown in Table 2 , 131 were tumor-private and 164 were TILs-private. The most frequently shared mutation was again BRCA1 p.Gln563Ter, which, however, was not detected in any of the 68 blood samples examined here, including 18 blood samples from patients with tumors carrying this mutation. The diversity of shared and private mutation patterns in tumor-enriched and TILs-enriched pairs is shown in Figure 3a . More mutations but at very low VAFs were identified in TILs-enriched samples (all p's < 0.001; Fig. 3b, Supporting Information Fig. S9) . The spectrum of genes with clonal mutations in tumorenriched samples was larger as compared to TILs-enriched samples (Fig. 3c) . Clearly, low VAF mutations in the TILsenriched samples might have derived from dispersed cancerous cells that occasionally constituted up to 20% of the cell population; similarly, low VAF mutations obtained in the tumor-enriched samples might have derived from infiltrating lymphocytes up to 40%, respectively (Supporting Information  Fig. S1 ).
Association of mutation patterns with patient outcome
Patient follow-up, response to treatment and outcome data are shown in Supporting Information Table S5 . Seventyseven patients (64.2%) experienced complete response. Response was not related to any standard clinicopathological parameter or single mutated gene (Supporting Information Table S6 ) evidently because of the small number of patients in each subgroup.
EBV positivity was strongly associated with better outcome, with 20% and 24% of the 110 EBV positive patients relapsing within the first 3 and 5 years, respectively (Supporting Information Table S7 ). Only 14 patients were EBV negative, reflecting inadequate statistical power for comparisons between the two groups. Single mutated genes were not significantly associated with outcome, as expected, since these seldom occurred individually while mutation combinations would fragmentize the already small cohort and further lower statistical power. EBV positive patients fared significantly better than EBV negative if no mutation was detected in their tumors ( Fig. 4a ; Supporting Information Table S7 ). Independently, of EBV status, stable tumors conferred significantly less relapses within 3 years compared to tumors of intermediate stability (Fig. 4b) , while the prognostic effect of BRCA1 mutations was associated with the status of genomic stability ( Fig.  4c ; Supporting Information Tables S7-S9). KRAS and PIK3CA mutations were also statistically significantly unfavorable in 
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Fountzilas et al. Cases also tested for germline mutations but found negative. 4 Pathogenic refers to cancer predisposition (germline mutation effect); functional implication of the same mutation in the tumor environment cannot be inferred from germline classification Abbreviations: VAF, variant allele frequency; VUS, variant of unknown significance. tumors of intermediate stability as compared to unstable tumors (Supporting Information Figs. S10 and S11), but the number of patients in each subgroup for these genes was too small. APOBEC over-expression and PD-L1 positivity were not associated with patient outcome.
For multivariate analyses, we used two models for the evaluation of tumor genotypes against outcome. As shown in Figure 4d and 4e for 3 years-PFS and in Supporting Information Table S9 for OS, EBV status was the only clinicopathological parameter independently predictive of outcome. The impact of mutation presence was significant for distinguishing EBV positive patients into those with better and worse prognosis. The unfavorable effect of BRCA1 mutations was restricted to patients with tumors of intermediate stability who experienced more relapses than those without mutations in these genes; these effects were not significant for OS (Supporting Information Table S9 ).
Discussion
In a series of Southeast European NPC, we performed highdepth targeted NGS and present two novel pieces of data: (a) the high prevalence of HRR gene and particularly BRCA1 mutations with mechanistic and clinical implications and (b) the presence of private mutations in the TILs component of NPC.
BRCA1 and HRR gene mutations were prevalent in the present series, other than reported for NPC from Southeast Asian patients. 9, 11 These two previous exploratory studies reported on mutations in BAP1, another HRR gene that was found mutated here as well, but there was only one BRCA2 mutation in the Lin study 9 that was not identified with the subsequently used targeted panel. The use of whole exome sequencing 9, 11 in comparison to our targeted high depth approach cannot have contributed to the apparent difference in the frequency of BRCA1/2 mutations between European and Asian NPC. Here, BRCA1/2 mutations were often clonal, some were recurrent and orthogonally validated, and hence unlikely to have been missed with low depth-omics methods, and also unlikely to represent false NGS findings in FFPE tissues. NPC are the result of long operating interactions between environmental carcinogens, including viral genomes and host genomes. Our finding may thus be related to geographical differences with respect to the diversity of EBV types worldwide, 29 environmental factors other than EBV that may affect mutagenicity and also to ethnic variations in host immune response, for example, as has been described for differences in HRR genes in healthy Cantonese. 30, 31 The majority of the observed recurrent BRCA1/2 mutations are classified as definitely pathogenic when inherited. However, in the examined tumors, these appeared to be somatic, because these were not identified in the germline of 68 Greek patients with available data. Unfortunately, peripheral blood samples from Romanian patients were not available; hence, we cannot comment on BRCA1/2-related predisposition for NPC development in this patient group. The differences with respect to mutational load and specific gene mutations between Greek and Romanian patients cannot be approached as effects of treatment (all samples were collected at baseline) or FFPE quality (no differences were observed). A vague evidence for a possible environmental effect in association with inherited genotypes might be the younger age of Romanian as compared to Greek patients; however, this is a hypothesis needing investigation at multiple levels (environment, virus strains, germline genotypes and their interactions). The recurrent orthogonally validated BRCA1 p.Gln563Ter (p.Q563*; rs80356898) is particularly interesting. This stop-gain mutation with a germline prevalence of 0.00004130 according to dbSNP and ExAC has been reported as a founder mutation in Slovenia and Austria 32 and also in other European countries. 33, 34 It is the first time that BRCA1 p.Gln563Ter is reported as recurrently somatic in any tumor type, which merits functional investigation.
NPC are classified as of low mutation burden. 35 Here, based on overall mutation and mutated gene numbers, we distinguished three classes of NPC: stable, intermediate and unstable, the latter being hypermutated and comprising up to 17% of the tumors. Despite the absence of germline mutations, all unstable tumors were BRCA1 mutant and their mutation patterns resembled the described mutation kataegis observed in BRCA1 mutation germline carriers, 36 linked to aberrant APOBEC deaminase function. APOBEC-mediated mutagenesis seems to operate for the acquisition of EBV-ness during mammary epithelial cell transformation, 37 while APOBEC-mediated mutation signatures have been revealed in NPC. 11 In line with the above, we also identified one of the APOBEC3 mutation signatures and found that APO-BEC3A/B and APOBEC3B overexpressing tumors had a higher rate of BRCA1 mutations, the recurrent p.Gln563Ter in particular, which is a novelty in NPC. This finding may be of interest for future therapeutics, since APOBECs are potential drug targets. 38 However, cause-and-effect between APOBECs, BRCA1 mutations and genomic instability cannot be inferred from our study; other than APOBEC3A/B, APO-BEC3C overexpression was linked to lower mutation burden, which may be explained by the prominent role of the 3C enzyme in EBV DNA editing and stabilization. 39 Hence, although the observed rate of instability may in part be attributed to APOBEC3A/B function, the different enzymes of this family may play diverse roles in the development of NPC, which needs to be taken into account for relevant research purposes.
Classically, EBV status is a major determinant of NPC patient outcome upon chemoradiotherapy, 40, 41 which was observed here as well. It seems, however, that only stable EBV positive tumors, that is, those without mutations, confer the anticipated favorable outcome as compared to EBV negative tumors. This on/off mutation effect on patient outcome has been described before 42 and it seems that it is not gene specific but rather reflects different oncogenic processes and tumor-host interactions operating in each class of tumors. Genomic instability in NPC seems clinically important because it affects drug-targetable genes and pathways. Patients with unstable tumors, all carrying multiple BRCA1 and HRR mutations, benefitted from the applied (IC)-CCRT. This is in-line with the reported benefit from platinum-based chemotherapy for patients with BRCA1 mutations and corresponding genomic instability in different tumor systems. 43, 44 Although we only examined approximately 100 genes, and hence may have missed further unstable tumors, these findings are clinically relevant and support the consideration of alternative treatment approaches, for example, PARPinhibitors in NPC.
The second novel piece of data concerns the presence of mutations in the TILs component of NPC. These mutations were mostly TILs private and non-clonal. Very few of these alterations were also present in the germline of informative patients, none of them pathogenic; hence, the mutations detected in the TILs compartment can be generally considered as somatic. Mutations in tumor leukocytes have previously been described in breast cancer 45 and were attributed to locally acting factors, which may also be the case for the examined NPC. Although we cannot exclude the exosomal origin of these mutations, 46 mutations and genomic instability induced by EBV in transforming and cancerous B lymphocytes 19, 20, 47 justify the development of a broad mutation spectrum in the lymphocytic component. Importantly though, the lymphocytic component in NPC is mostly composed of cytotoxic T lymphocytes 48 that are traditionally not considered to be infected by EBV or to produce lytic phase EBV proteins. It may be that this cellular environment is genetically altered prior to viral activation or perhaps triggers the virus to become pathogenic, possibly through the long proposed cell-cell fusion. 49 The fact that tumor cells and their environment that is rich in immune cells are both genomically altered offers a new dimension to the term lymphoepithelioma for NPC and a novel insight to the pathogenesis of this disease.
With respect to previously published gene and pathway alterations in NPC excluding BRCA1/2, we found TP53 mutations at a 22% rate, similar to 9 and higher than, 11 a high incidence of mutations in the PI3K pathway, including KRAS mutations that were absent in an Asian cohort, 10 and high incidence of mutations in chromatin modifiers and autophagy genes, similar to the Asian studies, 9,11 although unrelated to patient outcome. Finally, we have also identified mutations in immune response related genes, including PD-1 and PD-L1 that were not previously reported. Alterations in these genes are anticipated for EBV-related carcinomas, as described for gastric cancer. 50 Such mutations were not associated with PD-L1 protein expression in our series. We also did not observe any impact of PD-L1 positivity in tumor cells on patient outcome, other than the reported unfavorable effect of high PD-L1 expression on the overall survival in Korean patients with NPC. 51 However, the two studies are not directly comparable because different antibodies with different staining efficiency and probably specificity were used, which is prone to PD-L1 "misclassification" even for antibodies that have been extensively interrogated for diagnostic use. 52 Therefore, it appears mandatory to further investigate the impact of the PD1/PD-L1 checkpoint for possible therapeutic interventions in this lymphocyte-rich tumor.
In conclusion, the mutational contexture of Southeast European NPC appears to have similarities but also important differences as compared to the Southeast Asian models. The prevalence of assumed pathogenic somatic BRCA1 mutations and the accompanying degree of genomic instability in European NPC seems worth further pursuing for alternative treatments, such as PARP-inhibitors. We also report on genetic changes in the morphologically normal immune cell infiltrates of NPC which may be used as observational data for basic research studies on viral carcinogenesis and on the interference of the tumor microenvironment with the biologic characteristics of NPC.
